Treatment of severe lupus nephritis: the new horizon
Crossref DOI link: https://doi.org/10.1038/nrneph.2014.215
Published Online: 2014-11-25
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chan, Tak Mao
Text and Data Mining valid from 2014-11-25
Article History
First Online: 25 November 2014
Competing interests
: T.M.C. declares that he has acted as a consultant for the following companies: Astellas, Teva and Vifor Pharma.